Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hypophosphatemia caused by inappropriate urinary phosphate wasting is a frequent metabolic complication of the early period following kidney transplantation. Although previously considered to be caused by tertiary hyperparathyroidism, recent evidence suggests a primary role for persistently elevated circulating levels of the phosphorus-regulating hormone, FGF23. In the setting of a healthy renal allograft, markedly increased FGF23 levels from the dialysis period induce renal phosphate wasting and inhibition of calcitriol production, which contribute to hypophosphatemia. While such tertiary FGF23 excess and resultant hypophosphatemia typically abates within the first few weeks to months post-transplant, some recipients manifest persistent renal phosphate wasting. Furthermore, increased FGF23 levels have been associated with increased risk of kidney disease progression, cardiovascular disease, and death outside of the transplant setting. Whether tertiary FGF23 excess is associated with adverse transplant outcomes is unknown. In this article, we review the physiology of FGF23, summarize its relationship with hypophosphatemia after kidney transplantation, and speculate on its potential impact on long-term outcomes of renal allograft recipients.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalPediatric Transplantation
Volume15
Issue number1
DOIs
StatePublished - Feb 1 2011

Fingerprint

Hypophosphatemia
Kidney Transplantation
Kidney
Phosphates
Allografts
Transplants
Hyperparathyroidism
Calcitriol
Kidney Diseases
Phosphorus
Disease Progression
Dialysis
Cardiovascular Diseases
Hormones
fibroblast growth factor 23

Keywords

  • fibroblast growth factor 23
  • hypophosphatemia
  • kidney transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. / Seeherunvong, Wacharee; Wolf, Myles.

In: Pediatric Transplantation, Vol. 15, No. 1, 01.02.2011, p. 37-46.

Research output: Contribution to journalArticle

@article{712b5526586943a48c6d02bbda157698,
title = "Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation",
abstract = "Hypophosphatemia caused by inappropriate urinary phosphate wasting is a frequent metabolic complication of the early period following kidney transplantation. Although previously considered to be caused by tertiary hyperparathyroidism, recent evidence suggests a primary role for persistently elevated circulating levels of the phosphorus-regulating hormone, FGF23. In the setting of a healthy renal allograft, markedly increased FGF23 levels from the dialysis period induce renal phosphate wasting and inhibition of calcitriol production, which contribute to hypophosphatemia. While such tertiary FGF23 excess and resultant hypophosphatemia typically abates within the first few weeks to months post-transplant, some recipients manifest persistent renal phosphate wasting. Furthermore, increased FGF23 levels have been associated with increased risk of kidney disease progression, cardiovascular disease, and death outside of the transplant setting. Whether tertiary FGF23 excess is associated with adverse transplant outcomes is unknown. In this article, we review the physiology of FGF23, summarize its relationship with hypophosphatemia after kidney transplantation, and speculate on its potential impact on long-term outcomes of renal allograft recipients.",
keywords = "fibroblast growth factor 23, hypophosphatemia, kidney transplantation",
author = "Wacharee Seeherunvong and Myles Wolf",
year = "2011",
month = "2",
day = "1",
doi = "10.1111/j.1399-3046.2010.01405.x",
language = "English",
volume = "15",
pages = "37--46",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation

AU - Seeherunvong, Wacharee

AU - Wolf, Myles

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Hypophosphatemia caused by inappropriate urinary phosphate wasting is a frequent metabolic complication of the early period following kidney transplantation. Although previously considered to be caused by tertiary hyperparathyroidism, recent evidence suggests a primary role for persistently elevated circulating levels of the phosphorus-regulating hormone, FGF23. In the setting of a healthy renal allograft, markedly increased FGF23 levels from the dialysis period induce renal phosphate wasting and inhibition of calcitriol production, which contribute to hypophosphatemia. While such tertiary FGF23 excess and resultant hypophosphatemia typically abates within the first few weeks to months post-transplant, some recipients manifest persistent renal phosphate wasting. Furthermore, increased FGF23 levels have been associated with increased risk of kidney disease progression, cardiovascular disease, and death outside of the transplant setting. Whether tertiary FGF23 excess is associated with adverse transplant outcomes is unknown. In this article, we review the physiology of FGF23, summarize its relationship with hypophosphatemia after kidney transplantation, and speculate on its potential impact on long-term outcomes of renal allograft recipients.

AB - Hypophosphatemia caused by inappropriate urinary phosphate wasting is a frequent metabolic complication of the early period following kidney transplantation. Although previously considered to be caused by tertiary hyperparathyroidism, recent evidence suggests a primary role for persistently elevated circulating levels of the phosphorus-regulating hormone, FGF23. In the setting of a healthy renal allograft, markedly increased FGF23 levels from the dialysis period induce renal phosphate wasting and inhibition of calcitriol production, which contribute to hypophosphatemia. While such tertiary FGF23 excess and resultant hypophosphatemia typically abates within the first few weeks to months post-transplant, some recipients manifest persistent renal phosphate wasting. Furthermore, increased FGF23 levels have been associated with increased risk of kidney disease progression, cardiovascular disease, and death outside of the transplant setting. Whether tertiary FGF23 excess is associated with adverse transplant outcomes is unknown. In this article, we review the physiology of FGF23, summarize its relationship with hypophosphatemia after kidney transplantation, and speculate on its potential impact on long-term outcomes of renal allograft recipients.

KW - fibroblast growth factor 23

KW - hypophosphatemia

KW - kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=78751673627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751673627&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2010.01405.x

DO - 10.1111/j.1399-3046.2010.01405.x

M3 - Article

VL - 15

SP - 37

EP - 46

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 1

ER -